Nicholas Rebold

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections

Nicholas Rebold, Taylor Morrisette, Abdalhamid M Lagnf et al. · Open Forum Infectious Diseases · 2021 · 30 citations · Full text

Risk Factors for Carbapenem-Resistant <i>Enterobacterales</i> Clinical Treatment Failure

Nicholas Rebold, Abdalhamid M Lagnf, Sara Alosaimy et al. · Microbiology Spectrum · 2023 · 21 citations · Full text

High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production

Ashlan J. Kunz Coyne, Amer El Ghali, Kristen Lucas et al. · Open Forum Infectious Diseases · 2023 · 17 citations · Full text

Impact of Ceftolozane–Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections

Dana Holger, Nicholas Rebold, Sara Alosaimy et al. · Infectious Diseases and Therapy · 2022 · 13 citations · Full text

Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam

Sara Alosaimy, Abdalhamid M Lagnf, Athena L V Hobbs et al. · Clinical Infectious Diseases · 2022 · 12 citations